Synlogic, Inc. (SYBX): Price and Financial Metrics

Synlogic, Inc. (SYBX): $1.15

0.11 (+10.58%)

POWR Rating

Component Grades














  • SYBX scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.95% of US stocks.
  • SYBX's strongest trending metric is Stability; it's been moving up over the last 146 days.
  • SYBX ranks lowest in Momentum; there it ranks in the 9th percentile.

SYBX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for SYBX is 0.01 -- better than merely 7.11% of US stocks.
  • SYBX's price/sales ratio is 102.1; that's higher than the P/S ratio of 97.63% of US stocks.
  • Revenue growth over the past 12 months for Synlogic Inc comes in at 221.84%, a number that bests 96.36% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Synlogic Inc are AGTC, ARAV, ALT, VBLT, and VTGN.
  • SYBX's SEC filings can be seen here. And to visit Synlogic Inc's official web site, go to

SYBX Valuation Summary

  • SYBX's price/sales ratio is 570.7; this is 4928.19% higher than that of the median Healthcare stock.
  • SYBX's price/sales ratio has moved NA NA over the prior 72 months.
  • SYBX's price/sales ratio has moved NA NA over the prior 72 months.

Below are key valuation metrics over time for SYBX.

Stock Date P/S P/B P/E EV/EBIT
SYBX 2021-08-31 570.7 1.1 -2.5 -2.3
SYBX 2021-08-30 576.8 1.1 -2.5 -2.3
SYBX 2021-08-27 549.2 1.1 -2.4 -2.2
SYBX 2021-08-26 562.2 1.1 -2.4 -2.3
SYBX 2021-08-25 570.7 1.1 -2.5 -2.3
SYBX 2021-08-24 559.8 1.1 -2.4 -2.3

SYBX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SYBX has a Quality Grade of C, ranking ahead of 35.88% of graded US stocks.
  • SYBX's asset turnover comes in at 0.002 -- ranking 425th of 681 Pharmaceutical Products stocks.
  • RMTI, FATE, and FBRX are the stocks whose asset turnover ratios are most correlated with SYBX.

The table below shows SYBX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -0.437
2021-03-31 0.003 1 -0.440
2020-12-31 0.004 1 -0.412
2020-09-30 0.011 1 -0.366
2020-06-30 0.012 1 -0.338
2020-03-31 0.010 1 -0.291

SYBX Price Target

For more insight on analysts targets of SYBX, see our SYBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.33 Average Broker Recommendation 1.42 (Moderate Buy)

SYBX Stock Price Chart Interactive Chart >

Price chart for SYBX

SYBX Price/Volume Stats

Current price $1.15 52-week high $4.22
Prev. close $1.04 52-week low $0.88
Day low $0.96 Volume 94,800
Day high $1.15 Avg. volume 129,399
50-day MA $1.28 Dividend yield N/A
200-day MA $2.11 Market Cap 80.79M

Synlogic, Inc. (SYBX) Company Bio

Synlogic, Inc., a biopharmaceutical company, offers synthetic biotics that perform specific metabolic functions from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It provides SYNB1010 for urea cycle disorder, a synthetic biotic that is designed to remove excess ammonia from the blood; and SYNB2010 for phenylketonuria, a synthetic biotic that is designed to remove excess phenylalanine from the blood. The company was founded in 2013 and is based in Cambridge, Massachusetts.

SYBX Latest News Stream

Event/Time News Detail
Loading, please wait...

SYBX Latest Social Stream

Loading social stream, please wait...

View Full SYBX Social Stream

Latest SYBX News From Around the Web

Below are the latest news stories about Synlogic Inc that investors may wish to consider to help them evaluate SYBX as an investment opportunity.

Synlogic To Present at Upcoming Investor and Industry Conferences

CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that members of the executive team will present at the following investor and industry conferences: BIO CEO & Investor Conference: Molly Harper, Chief Business Officer, will present at 10:00 am EST on Monday, February 14, 2022.11th Annual SVB Le

Yahoo | February 8, 2022

Will Synlogic (NASDAQ:SYBX) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | January 11, 2022

Synlogic Announces Progress Toward 2022 Clinical Milestones and Participation at Upcoming Investor Conferences

- On track to initiate Phase 3 for treatment of phenylketonuria (PKU) in H2 2022 - - Additional milestones include multiple clinical read-outs across programs including enteric hyperoxaluria and homocystinuria (HCU) during 2022 - CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today provided an update on pro

Yahoo | January 6, 2022

H.C. Wainwright Thinks Synlogic’s Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Synlogic (SYBX – Research Report) today and set a price target of $7.00. The company's shares closed last Friday at $2.42, close to its 52-week low of $2.07. According to, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Synlogic has an analyst consensus of Strong Buy, with a price target consensus of $7.00.

Howard Kim on TipRanks | January 3, 2022

What Makes Synlogic, Inc. (SYBX) a New Buy Stock

Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | December 24, 2021

Read More 'SYBX' Stories Here

SYBX Price Returns

1-mo 6.48%
3-mo -53.44%
6-mo -52.48%
1-year -71.95%
3-year -87.32%
5-year -90.16%
YTD -52.48%
2021 12.04%
2020 -16.28%
2019 -63.20%
2018 -27.73%
2017 -23.02%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0746 seconds.